rhodioloside has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Y; He, Y; Hu, Z; Lv, Z; Meng, X; Mou, X; Pan, Y; Zhao, X | 1 |
| Joung, YH; Kang, DY; Kim, DH; Lee, HG; Park, YM; Sp, N; Yang, YM | 1 |
2 other study(ies) available for rhodioloside and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Engineered Red Blood Cell Membrane-Coating Salidroside/Indocyanine Green Nanovesicles for High-Efficiency Hypoxic Targeting Phototherapy of Triple-Negative Breast Cancer.
Topics: Cell Line, Tumor; Erythrocyte Membrane; Glucosides; Humans; Hypoxia; Indocyanine Green; Nanoparticles; Phenols; Photochemotherapy; Phototherapy; Triple Negative Breast Neoplasms | 2022 |
Salidroside inhibits migration, invasion and angiogenesis of MDA‑MB 231 TNBC cells by regulating EGFR/Jak2/STAT3 signaling via MMP2.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Janus Kinase 2; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Phenols; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2018 |